Study Name:
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Targeted Disease(s):
COPD
Purpose of Study:
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Study Dates:
December 1, 2022 - June 30, 2025
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Synexus Clinical Research
Sponsors:
Hoffman-La Roche
ClinicalTrails.gov Identifier:
NCT05595642
